Artichoke leaf extract in the body
Artichoke leaf extract is not a nutrient, and the body has no daily requirement for it. Globe artichoke belongs to the Asteraceae family and comes from the Mediterranean basin. Its wild ancestor is wild cardoon; cultivated cardoon, the same species, is grown for its leaf stalks. The edible portion is typically only 30–40% of the plant's biomass.
Terms and sources
- Asteraceae family
- Sonnante et al., Annals of Botany, 2007.
- wild ancestor
- Wild cardoon is the progenitor of both crops. Sonnante et al., Annals of Botany, 2007.
- 30–40% of the plant's biomass
- The stems and leaves are discarded or used as animal feed or fertilizer. Olas, Nutrients, 2024. The review summarizes earlier work.
The main phenolic compounds of the leaf extract are caffeoylquinic acids and flavonoids. Cynarin is one of the dicaffeoylquinic acids. Of all parts of the plant, the leaves hold the most luteolin. Cynarin rises as the plant grows, from 0.01% to 0.05% of dry matter. Leaves and stems also hold bitter compounds called sesquiterpenes, such as cynaropicrin.
Terms and sources
- caffeoylquinic acids
- Mono- and dicaffeoylquinic acids, such as chlorogenic acid and cynarin, and caffeic acid. Wittemer et al., Phytomedicine, 2005.
- flavonoids
- Such as luteolin-7-O-glucoside. Wittemer et al., Phytomedicine, 2005.
- dicaffeoylquinic acids
- Sonnante et al., Annals of Botany, 2007.
- the most luteolin
- Olas, Nutrients, 2024.
- 0.01% to 0.05%
- Olas, Nutrients, 2024. The review summarizes earlier analyses.
- sesquiterpenes
- The review says they are believed to taste very bitter. Olas, Nutrients, 2024.
In 14 healthy volunteers, the extract's own caffeoylquinic acids and luteolin glycosides were not found in blood or urine. Instead, blood and urine held their breakdown products, such as caffeic, ferulic and isoferulic acid. These peaked within 1 hour; dihydrocaffeic and dihydroferulic acid peaked only after 6–7 hours. Luteolin appeared only in bound forms, with a peak within half an hour. In another study of 10 volunteers, urine held ferulic, isoferulic, dihydroferulic and vanillic acid after the extract.
Terms and sources
- 14 healthy volunteers
- Each took two different leaf extracts, one after the other. Wittemer et al., Phytomedicine, 2005. The first author's affiliation is Lichtwer Pharma AG.
- breakdown products
- All but dihydroferulic acid were present as sulfates or glucuronides. Wittemer et al., Phytomedicine, 2005.
- 6–7 hours
- The authors read this as two different routes of breakdown. Wittemer et al., Phytomedicine, 2005.
- bound forms
- As sulfate or glucuronide, not as the glucoside in the extract and not as free luteolin. Wittemer et al., Phytomedicine, 2005.
- 10 volunteers
- The abstract says three capsules of 320 mg artichoke extract, given every 4 hours (at 0, 4 and 8 hours). It does not say which part of the plant was used. Rechner et al., Free Radical Research, 2001.
Neither the US complementary health center (NCCIH) nor the NIH Office of Dietary Supplements has a fact sheet on artichoke. So the safety text on this page comes from the EU herbal medicine monograph.
Terms and sources
- a fact sheet
- Artichoke is not in NCCIH's Herbs at a Glance list or in the ODS list of fact sheets. National Center for Complementary and Integrative Health; NIH Office of Dietary Supplements.
The European Medicines Agency's EU herbal medicine monograph on artichoke leaf covers it as a traditional herbal medicine. For these herbal medicines, it states for children: "The use in children under 12 years of age is not recommended (see section 4.4 ‘Special warnings and precautions for use’)." On how long to use it, it states: "If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted." Under contraindications, it lists: "Hypersensitivity to the active substance or to plants of the Asteraceae family (Compositae)." It also lists: "Obstruction of bile duct, cholangitis, liver disease, gallstones and any other biliary disorders that require medical supervision and advice." Under special warnings, it adds: "The use in children under 12 years of age has not been established due to lack of adequate data." Under interactions with other medicines, it states: "None reported." The monograph also states: "Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended." It adds: "No fertility data available." On driving, it states: "No studies on the effect on the ability to drive and use machines have been performed." As side effects, it notes: "Slight diarrhoea with abdominal spasm, epigastric complaints like nausea, and heartburn have been reported. The frequency is not known." It adds: "Allergic reactions may occur. The frequency is not known." And: "If other adverse reactions not mentioned above occur, a doctor or a qualified health care practitioner should be consulted." On taking too much, it states: "No case of overdose has been reported." On laboratory safety data, it states: "Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC, unless necessary for the safe use of the product." It adds: "Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed." In a later periodic review, the EMA committee found no new data that called for a revision of the monograph.
Terms and sources
- EU herbal medicine monograph
- Cynara cardunculus L. (syn. Cynara scolymus L.), folium. The quotes below are from it. EU herbal medicine monograph on artichoke leaf, European Medicines Agency.
- contraindications
- Reasons not to use the product, in medicine labeling terms. EU herbal medicine monograph on artichoke leaf, European Medicines Agency.
- a later periodic review
- Reports in the EU safety database were non-serious. The committee found them covered by the side-effect section. It notes a rat study where rosuvastatin blood levels were lower with the extract. The committee did not find this a reason to revise. Addendum to the assessment report on artichoke leaf, European Medicines Agency.










